Skip to main content
. 2020 Nov 5;11(11):951. doi: 10.1038/s41419-020-03146-w

Fig. 5. GDC-0349 oral administration inhibits NSCLC xenograft growth in SCID mice.

Fig. 5

A549 xenografts-bearing SCID mice were randomly assigned into three groups (10 mice per group); Mice received GDC-0349 treatment (oral administration, 10 or 30 mg/kg body weight, daily for 21 days) or vehicle control treatment (“Veh”); Tumor volumes (a) and mice body weights (d) were recorded every seven days. Estimated daily tumor growth was calculated using the described formula (b); Tumors of all three groups were isolated and weighted at Day-35 (c). At Day-7 and Day-14, one tumor from each group was isolated (total six tumors), and tumor lysates achieved; Expression of listed proteins was shown (e and g); Relative SphK1 activity was tested (f),with GSH/GSSG ratio examined as well (h). NSCLC-1 xenografts-bearing SCID mice were treated with GDC-0349 (oral administration, 30 mg/kg body weight, daily for 21 days) or vehicle control; Tumor volumes (i) and mice body weights (k) were recorded every seven days. Estimated daily tumor growth was calculated by the formula: (tumor volume at Day-42—tumor volume at Day-0)/42 (j). The data are presented as mean ± standard deviation (SD). *p < 0.05 vs. “Veh” group.